Cilostazol This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.
WANTED! 10 people to support MedWorm and trial MedWorm Search Find out more here...
This page shows you the latest news and research items in this category.
Differential Effect of Phosphodiesterase-3 Inhibitors on Sympathetic Hyperinnervation in Healed Rat Infarcts.
Conclusions: Unlike milrinone, cilostazol has therapeutic neutrality in arrhythmias because of adenosine uptake inhibition, which antagonizes the PDE-3-induced increase of sympathetic reinnervation via mediation of an adenosine A1 receptor-mediated antioxidation. PMID: 24304537 [PubMed - as supplied by publisher] (Source: Circulation Journal)
Source: Circulation Journal - December 4, 2013 Category: Cardiology Authors: Lee TM, Lin SZ, Chang NC Tags: Circ J Source Type: research
Cilostazol decreases total atrial conduction time in patients with peripheral artery disease.
CONCLUSION: Our results showed that 200 mg cilostazol treatment decreased TACT duration in patients with peripheral artery disease, which may also prevent the development and/or recurrence of atrial fibrillation (AF). PMID: 24280344 [PubMed - as supplied by publisher] (Source: Perfusion)
Source: Perfusion - November 26, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Alizade E, Sahin M, Simsek Z, Açar G, Bulut M, Güler A, Avci A, Kalkan M, Pala S, Akçakoyun M, Esen A Tags: Perfusion Source Type: research
Preparation and Characterization of Microemulsion of Cilostazol for Enhancement of Oral Bioavailability.
In this study, Capmul MCM C8 (glycerol monocaprylate) based MEs containing Tween 20(polysorbate 20) and/or Labrafil M 1944(poly oxyglycerides) as surfactant(S) and Transcutol P(diethyl glycol monoethyl ether) as cosurfactant(CoS) were studied as potential delivery systems of cilostazol. A number of such systems were prepared containing different S:CoS ratios(1:1, 2:1 and 3:1) based on phase diagrams. Loading of cilostazol was selected as per solubilization capacity and were characterized for pH, viscosity, conductivity, particle size, zeta potential and % transmittance. The MEs systems were further investigated for chemica...
Source: Current Drug Delivery - November 26, 2013 Category: Drugs & Pharmacology Authors: Patel SG, Rajput SJ, Groshev A, Sutariya VB Tags: Curr Drug Deliv Source Type: research
Attenuation of β‐amyloid‐induced tauopathy via activation of CK2α/SIRT1: Targeting for cilostazol
In conclusion, increased cAMP‐dependent protein kinase‐linked CK2/SIRT1 expression by cilostazol can be a therapeutic strategy to suppress the tau‐related neurodegeneration in the AD brain. © 2013 Wiley Periodicals, Inc. (Source: Journal of Neuroscience Research)
Source: Journal of Neuroscience Research - November 19, 2013 Category: Neuroscience Authors: Hye Rin Lee, Hwa Kyoung Shin, So Youn Park, Hye Young Kim, Won Suk Lee, Byung Yong Rhim, Ki Whan Hong, Chi Dae Kim Tags: Research Article Source Type: research
Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
Abstract The Editors welcome topical correspondence from readers relating to articles published in the Journal. Responses should be sent electronically via the BJS website (www.bjs.co.uk). All letters will be reviewed and, if approved, appear on the website. A selection of these will be edited and published in the Journal. Letters must be no more than 250 words in length. PMID: 24227374 [PubMed - in process] (Source: The British Journal of Surgery)
Source: The British Journal of Surgery - November 17, 2013 Category: Surgery Authors: Roset PN Tags: Br J Surg Source Type: research
Authors' reply: Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
Source: The British Journal of Surgery - November 17, 2013 Category: Surgery Authors: Authors' reply: Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638). Tags: Br J Surg Source Type: research
Authors' reply: Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630–1638)
(Source: British Journal of Surgery)
Source: British Journal of Surgery - November 14, 2013 Category: Surgery Authors: J.W. Stevens, E. Simpson, S. Harnan, H. Squires, Y. Meng, S. Thomas, J. Michaels, G. Stansby Tags: Your Views Source Type: research
Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630–1638)
The Editors welcome topical correspondence from readers relating to articles published in the Journal. Responses should be sent electronically via the BJS website (www.bjs.co.uk). All letters will be reviewed and, if approved, appear on the website. A selection of these will be edited and published in the Journal. Letters must be no more than 250 words in length. (Source: British Journal of Surgery)
Source: British Journal of Surgery - November 14, 2013 Category: Surgery Authors: P. N. Roset Tags: Your Views Source Type: research
Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention
BackgroundWe investigated the pharmacodynamic effect of cilostazol addition (100 mg twice, Triple) or clopidogrel doubling (150 mg daily, Double) on standard dual antiplatelet therapy in type 2 diabetes mellitus (T2DM) patients with clopidogrel resistance undergoing a percutaneous coronary intervention. Methods and resultsThis was a prospective, randomized, cross-over platelet function study. Percent inhibition less than 20% was used as the cutoff value of clopidogrel resistance. After percutaneous coronary intervention, a total of 50 T2DM patients with clopidogrel resistance were assigned to receive cilostazol 100 mg twic...
Source: Coronary Artery Disease - November 8, 2013 Category: Cardiology Tags: Original Research Source Type: research
Cilostazol, a selective Type III phosphodiesterase inhibitor: prevention of cervical myelopathy in a rat chronic compression model.
Conclusions These results indicate that cilostazol is neuroprotective in the chronically compressed cervical cord and is potentially useful in the treatment of cervical spondylotic myelopathy. PMID: 24206033 [PubMed - as supplied by publisher] (Source: Journal of Neurosurgery.Spine)
Source: Journal of Neurosurgery.Spine - November 8, 2013 Category: Neurosurgery Authors: Yamamoto S, Kurokawa R, Kim P Tags: J Neurosurg Spine Source Type: research
Comparison of On-Treatment Platelet Reactivity Between Triple Antiplatelet Therapy With Cilostazol and Standard Dual Antiplatelet Therapy in Patients Undergoing Coronary Interventions: A Meta-Analysis
Conclusion: Addition of cilostazol to conventional dual antiplatelet therapy significantly lowers platelet reactivity and may explain a decrease in thromboembolic events following coronary intervention; however, additional studies evaluating clinical outcomes will be helpful to determine the benefit of triple antiplatelet therapy. (Source: Journal of Cardiovascular Pharmacology and Therapeutics)
Source: Journal of Cardiovascular Pharmacology and Therapeutics - November 8, 2013 Category: Cardiology Authors: Panchal, H. B., Shah, T., Patel, P., Albalbissi, K., Molnar, J., Coffey, B., Khosla, S., Ramu, V. Tags: Clinical Studies Source Type: research
Treatment Options for Patients With Poor Clopidogrel Response
A significant percentage of patients demonstrate a poor antiplatelet response to clopidogrel. With the emergence of testing for genetic variations in drug-metabolizing enzyme function and testing for platelet function, it is becoming more common to identify patients as poor responders to clopidogrel. This leaves the clinician in a difficult situation when confronted with a patient deemed to be a poor clopidogrel responder as there is no clear therapeutic strategy for treating these patients. In this situation, a number of alternatives to conventional dosing of clopidogrel have been investigated, including increasing the do...
Source: Cardiology in Review - November 1, 2013 Category: Cardiology Tags: Feature Curbside Consult Source Type: research
Cilostazol Reduces Angiographic Restenosis After Endovascular Therapy for Femoropopliteal Lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol Study
Cilostazol reduces angiographic restenosis for femoropopliteal lesions after percutaneous transluminal angioplasty with provisional nitinol stenting. Use of nitinol stents has improved long-term outcomes of endovascular therapy for femoropopliteal lesions compared with balloon angioplasty alone (Schillinger M et al, N Engl J Med 2006;354:1879-88; and Laird JR et al, Circ Cardiovasc Interv 2010;3:267-76). However, even with the use of stents, there remains a 20% to 50% incidence of restenosis at 1 year. The present study was designed to determine, using angiographic follow-up, whether treatment with cilostazol reduces rest...
Source: Journal of Vascular Surgery - October 27, 2013 Category: Surgery Authors: O. Iida, H. Yokoi, Y. Soga, STOP-IC investigators Tags: Abstracts Source Type: research
Probucol and cilostazol exert a combinatorial anti-atherogenic effect in cholesterol-fed rabbits
Conclusion: We found that the PB group and the PB+CZ group exhibited a reduction in the lesion areas (70% in the PB+CZ group, 56% in the PB group) compared with the vehicle group. However, although PB alone and PB+CZ led to a reduction in the lesion size, the histological analysis revealed that only PB+CZ significantly decreased the macrophage accumulation and smooth muscle cell proliferation in the lesions compared with the vehicle group. The plasma levels of total cholesterol in the PB+CZ group were decreased compared with the vehicle group, Moreover, PB+CZ exerted obvious anti-oxidant and anti-inflammatory effects. Inte...
Source: Thrombosis Research - October 2, 2013 Category: Hematology Authors: Yulong Chen, Sihai Zhao, Bingqiao Huang, Yanli Wang, Yafeng Li, Ahmed Bilal Waqar, Ruihan Liu, Liang Bai, Jianglin Fan, Enqi Liu Tags: Platelets and Cell Biology Source Type: research
Cilostazol Is Associated with Improved Outcomes after Peripheral Endovascular Interventions: A Meta-Analysis
While cilostazol is commonly used as an adjunct following peripheral vascular interventions (PVI), its efficacy remains uncertain. We assessed the effect of cilostazol on outcomes following PVI using meta-analytic techniques. (Source: Journal of Vascular Surgery)
Source: Journal of Vascular Surgery - September 30, 2013 Category: Surgery Authors: Courtney J. Warner, Spencer W. Greaves, Robin J. Larson, Randall R. De Martino, Richard J. Powell, Daniel B. Walsh, Philip P. Goodney Tags: Abstracts from the 2013 Eastern Vascular Society Annual Meeting Source Type: research
Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease
ConclusionTAPT after drug-eluting stent implantation in patients with uLMCAD did not improve the long-term clinical outcome when compared with conventional DAPT, although it was a safe strategy. (Source: Coronary Artery Disease)
Source: Coronary Artery Disease - September 30, 2013 Category: Cardiology Tags: Original Research Source Type: research
Comparison of Dual Versus Triple Antiplatelet Therapy After Drug-Eluting Stent According to Stent Length (from the Pooled Analysis of DECLARE Trials)
In conclusion, the triple group had a significantly reduced ISR in patients with >40-mm stent length after DES implantation compared with the dual group. Therefore, this suggestion for use of triple antiplatelet therapy could be easily applied after DES implantation in routine clinical practice. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - September 23, 2013 Category: Cardiology Authors: Seung-Whan Lee, Jong-Young Lee, Jung-Min Ahn, Duk-Woo Park, Seungbong Han, Yong Kyu Park, Woo Seok Lee, Jeong Yoon Jang, Chang Hee Kwon, Gyung-Min Park, Young-Rak Cho, Won-Jang Kim, Soo-Jin Kang, Young-Hak Kim, Cheol Whan Lee, Jae-Joong Kim, Seong-Wook Pa Tags: Coronary Artery Disease Source Type: research
Cilostazol Ameliorates Warfarin-Induced Hemorrhagic Transformation After Cerebral Ischemia in Mice [Basic Sciences]
Conclusions— Cilostazol reduced the warfarin-related risk of HT after ischemia by protecting the vascular endothelial cells. This result suggested that cilostazol administration in patients with acute ischemic stroke might reduce HT. (Source: Stroke)
Source: Stroke - September 23, 2013 Category: Neurology Authors: Kitashoji, A., Egashira, Y., Mishiro, K., Suzuki, Y., Ito, H., Tsuruma, K., Shimazawa, M., Hara, H. Tags: Cerebrovascular disease/stroke, Animal models of human disease, Other anticoagulants, Intracerebral Hemorrhage, Anticoagulants Basic Sciences Source Type: research
Two Antiplatelet Add-on Regimens About Equal (CME/CE)
(MedPage Today) -- Adding cilostazol (Pletal) to standard dual antiplatelet therapy performed as well as doubling the dose of clopidogrel (Plavix) after implantation of a drug-eluting stent, the HOST-ASSURE study showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 17, 2013 Category: Cardiology Source Type: news
J wave syndromes: Molecular and cellular mechanisms
Abstract: An early repolarization (ER) pattern in the ECG, consisting of J point elevation, distinct J wave with or without ST segment elevation or slurring of the terminal part of the QRS, was long considered a benign electrocardiographic manifestation. Experimental studies a dozen years ago suggested that an ER is not always benign, but may be associated with malignant arrhythmias. Validation of this hypothesis derives from recent case–control and population-based studies showing that an ER pattern in inferior or infero-lateral leads is associated with increased risk for life-threatening arrhythmias, termed early repol...
Source: Journal of Electrocardiology - September 9, 2013 Category: Cardiology Authors: Charles Antzelevitch Tags: Session II: J wave syndromes and sudden cardiac death. From cell to bedside - Chair: Charles Antzelevitch, Co-Chair: Peter Macfarlane Source Type: research
Impaired platelet P2Y12 inhibition by thienopyridines * in chronic kidney disease: mechanisms, clinical relevance * and pharmacological options
Patients with chronic kidney disease (CKD) represent an increasing proportion of the population undergoing percutaneous coronary intervention (PCI) and up to 40% of the patients treated for acute coronary syndrome (ACS). Several studies and registries in the setting of ACS and elective PCI have reported a negative association between CKD and mortality, stent thrombosis, post-procedural ischaemic events and bleeding events. Pharmacological inhibition of the adenosine diphosphate receptor by thienopyridines or ticagrelor and disruption of the cyclooxygenase pathway by aspirin constitute the current standards of care to preve...
Source: Nephrology Dialysis Transplantation - September 6, 2013 Category: Urology & Nephrology Authors: Morel, O., Muller, C., Jesel, L., Moulin, B., Hannedouche, T. Tags: REVIEW - CLINICAL SCIENCE AND OUTCOME RESEARCH IN NEPHROLOGY Source Type: research
Comparison of peri-procedural platelet inhibition with prasugrel versus adjunctive cilostazol to dual anti-platelet therapy in patients with ST segment elevation myocardial infarction.
CONCLUSION: Our study demonstrates that prasugrel could produce a significantly greater peri-procedural as well as in-hospital IPA compared with TAP in patients with STEMI undergoing primary PCI. PMID: 24012432 [PubMed - as supplied by publisher] (Source: Journal of Cardiology)
Source: Journal of Cardiology - September 5, 2013 Category: Cardiology Authors: Park KH, Jeong MH, Lee KH, Sim DS, Yoon HJ, Yoon NS, Kim KH, Park HW, Hong YJ, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC Tags: J Cardiol Source Type: research
The effect of ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy Korean subjects
ConclusionsCo‐administration of GBE showed no statistically significant effects on the pharmacokinetics of cilostazol in healthy subjects. The long‐term large cohort clinical study seems to be remained to evaluate the possible pharmacodynamic interaction between cilostazol and GBE, since there was remarkable, but no statistically significant, increase of platelet aggregation inhibition. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - September 3, 2013 Category: Drugs & Pharmacology Authors: Ho‐Sook Kim, Ga‐young Kim, Chang‐Woo Yeo, Minkyung Oh, Jong‐lyul Ghim, Ji‐Hong Shon, Eun‐Young Kim, Dong‐Hyun Kim, Jae‐Gook Shin Tags: Clinical trials Source Type: research
Diagnosis and treatment of peripheral arterial disease.
Abstract Peripheral arterial disease (PAD) is atherosclerosis leading to narrowing of the major arteries distal to the aortic arch. The most common presenting symptom is claudication; however, only 10% of patients have classic claudication. Approximately 8 to 12 million Americans have PAD, including 15% to 20% of adults older than 70 years. The ankle-brachial index (ABI) can be used to screen for and diagnose PAD in the primary care setting. An ABI of less than 0.9 is associated with a two- to fourfold increase in relative risk for cardiovascular events and all-cause mortality. To improve cardiovascular risk strati...
Source: American Family Physician - September 1, 2013 Category: Primary Care Authors: Hennion DR, Siano KA Tags: Am Fam Physician Source Type: research
Comparison of Triple Anti-Platelet Therapy and Dual Anti-Platelet Therapy in Patients With Acute Myocardial Infarction Who Had No-Reflow Phenomenon During Percutaneous Coronary Intervention.
Conclusions: Triple anti-platelet therapy seems to be superior to dual anti-platelet therapy in patients with AMI who had no-reflow phenomenon during PCI. PMID: 23986083 [PubMed - as supplied by publisher] (Source: Circulation Journal)
Source: Circulation Journal - August 29, 2013 Category: Cardiology Authors: Lee KH, Ahn Y, Kim SS, Rhew SH, Jeong YW, Jang SY, Cho JY, Jeong HC, Park KH, Yoon NS, Sim DS, Yoon HJ, Kim KH, Hong YJ, Park HW, Kim JH, Cho JG, Park JC, Jeong MH, Cho MC, Kim CJ, Kim YJ, KAMIR (Korea Acute Myocardial Infarction Registry) Investigators Tags: Circ J Source Type: research
Efficacy and Safety of Triple Antiplatelet Therapy in Obese Patients Undergoing Stent Implantation
We evaluated the impact of triple antiplatelet therapy on platelet reactivity, reducing cardiovascular events and the safety in obese patients undergoing coronary stenting. Obese patients (n = 428) undergoing coronary stenting were randomly assigned to 2 groups: standard dual group (clopidogrel plus aspirin, n = 215) and triple group (n = 213); adjunctive cilostazol was added to the dual group treatment. Platelet reactivity was assessed at baseline and at 1-year follow-up by conventional aggregometry. Major adverse cardiovascular events, stent thrombosis, target lesion revascularization (TLR), target vessel revascularizati...
Source: Angiology - August 29, 2013 Category: Cardiology Authors: Gao, W., Zhang, Q., Ge, H., Guo, Y., Zhou, Z. Tags: Hemostasis Source Type: research
Age-Related Decline in Oligodendrogenesis Retards White Matter Repair in Mice [Basic Sciences]
Conclusions— An age-related decline in cyclic AMP response element-binding protein–mediated oligodendrogenesis may compromise endogenous white matter repair mechanisms, and therefore, drugs that activate cyclic AMP response element-binding protein signaling provide a potential therapeutic approach for treating white matter injury in aging brains. (Source: Stroke)
Source: Stroke - August 26, 2013 Category: Neurology Authors: Miyamoto, N., Pham, L.-D. D., Hayakawa, K., Matsuzaki, T., Seo, J. H., Magnain, C., Ayata, C., Kim, K.-W., Boas, D., Lo, E. H., Arai, K. Tags: Animal models of human disease, Other Stroke Treatment - Medical, Other Vascular biology Basic Sciences Source Type: research
RhoA/ROCK-dependent pathway is required for TLR2-mediated IL-23 production in human synovial macrophages: Suppression by cilostazol.
In this study, we investigated whether the RhoA/Rho-kinase pathway is required to elevate TLR2-mediated IL-23 production in synovial macrophages from patients with rheumatoid arthritis (RA), and then examined the suppressive effect of cilostazol on these pathways. IL-23 production was elevated by lipoteichoic acid (LTA), a TLR2 ligand, and this elevation was more prominent in RA macrophages than in those from peripheral blood of normal control. LTA increased the activation of RhoA in association with increased the nuclear translocation of NF-κB and its DNA-binding activity. Pretreatment of RA macrophages with the pharmaco...
Source: Biochemical Pharmacology - August 22, 2013 Category: Drugs & Pharmacology Authors: Park SY, Lee SW, Lee WS, Rhim BY, Lee SJ, Kwon SM, Hong KW, Kim CD Tags: Biochem Pharmacol Source Type: research
Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome
Conclusions: Our study identifies milrinone as a more potent alternative to cilostazol for reversing the repolarization defects responsible for the electrocardiographic and arrhythmic manifestations of Brugada syndrome. Both drugs normalize ST-segment elevation and suppress arrhythmogenesis in experimental models of Brugada syndrome. (Source: Heart Rhythm)
Source: Heart Rhythm - August 5, 2013 Category: Cardiology Authors: Tamás Szél, István Koncz, Charles Antzelevitch Tags: Experimental Genetic Source Type: research
Impact of cilostazol on the progression of carotid atherosclerosis in patients with retinal vascular occlusion
In conclusion, cilostazol potently inhibited the progression of carotid IMT and may play a role in the early carotid plaque regression in patients with retinal vascular occlusion. This article is protected by copyright. All rights reserved. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - August 1, 2013 Category: Cardiology Authors: Seong‐Man Kim, Kyoung‐Im Cho Tags: Original Research Article Source Type: research
Differential Impact of Cilostazol on Restenosis According to Implanted Stent Type (from a Pooled Analysis of Three DECLARE Randomized Trials)
In conclusion, add-on cilostazol effectively reduced restenosis in patients at high risk for restenosis, particularly in those receiving SES, suggesting the sustainable utility of add-on cilostazol therapy in newer generation drug-eluting stents with comparable efficacy with that of SES. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - July 26, 2013 Category: Cardiology Authors: Seung-Whan Lee, Jung-Min Ahn, Seungbong Han, Gyung-Min Park, Young-Rak Cho, Woo-Seok Lee, Jeong-Yoon Jang, Chang-Hee Kwon, Jong-Young Lee, Won-Jang Kim, Soo-Jin Kang, Young-Hak Kim, Cheol-Whan Lee, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park Tags: Coronary Artery Disease Source Type: research
Thermal Taste and Anti-Aspiration Drugs: a Novel Drug Discovery against Pneumonia.
Abstract Despite the development of strong antibiotics, the pneumonia death is increasing all over the world in these decades. Among the people who died of pneumonia, the majority were 65 years old or over. Although pneumonia is recently categorized into several entities, aspiration pneumonia is included all entities. Therefore, targeting dysphagia and aspiration to treat pneumonia is a promising strategy and anti-aspiration drugs will be a part of pneumonia treatment. The swallowing reflex in elderly people was temperature-sensitive and the improvement of swallowing reflex by temperature stimuli could be mediated ...
Source: Current Pharmaceutical Design - July 26, 2013 Category: Drugs & Pharmacology Authors: Ebihara S, Ebihara T, Gui P, Osaka K, Sumi Y, Kohzuki M Tags: Curr Pharm Des Source Type: research
Cilostazol strengthens the endothelial barrier of postcapillary venules from the rat mesentery in situ.
CONCLUSION: Cilostazol appears to tighten the endothelial barrier in situ, at least in part by inhibiting the cAMP-degrading enzyme in the endothelium. PMID: 23858026 [PubMed - as supplied by publisher] (Source: Phlebology)
Source: Phlebology - July 15, 2013 Category: Internal Medicine Authors: Sugiura Y, Morikawa T, Takenouchi T, Suematsu M, Kajimura M Tags: Phlebology Source Type: research
Meta-Analysis of Cilostazol Versus Aspirin for the Secondary Prevention of Stroke
In conclusion, compared with aspirin, cilostazol is associated with significantly less hemorrhagic stroke, the combined end point of stroke, myocardial infarction, and vascular death, and total hemorrhagic events, with numerically fewer gastrointestinal bleeds when used for the secondary prevention of stroke. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - July 8, 2013 Category: Cardiology Authors: James J. DiNicolantonio, Carl J. Lavie, Hassan Fares, Arthur R. Menezes, James H. O'Keefe, Sripal Bangalore, Franz H. Messerli Tags: Miscellaneous Source Type: research
Randomized Pilot Trial Between Prostaglandin I2 Analog and Anti‐Platelet Drugs on Peripheral Arterial Disease in Hemodialysis Patients
Abstract The effect of the prostaglandin I2 analog, beraprost sodium (BPS), on hemodialysis (HD) patients with peripheral arterial disease (PAD) has not been fully elucidated. The effect of BPS was compared to that of PAD drugs in HD patients with PAD in a multicenter randomized prospective interventional pilot study (J‐PADD). Seventy‐two PAD patients on HD were entered and randomly divided into two groups; that is, BPS group (Group A: n = 35) and PAD drug (cilostazol or sarpogrelate) group (Group B: n = 37). Primary endpoint was changes in skin perfusion pressure (SPP). Kidney Disease Quality of Life (KDQOL) s...
Source: Therapeutic Apheresis and Dialysis - July 3, 2013 Category: Hematology Authors: Takayasu Ohtake, Motoyoshi Sato, Ryoichi Nakazawa, Morihiro Kondoh, Takehiko Miyaji, Hidekazu Moriya, Sumi Hidaka, Shuzo Kobayashi Tags: Original Article Source Type: research
Cilostazol attenuates spontaneous microaggregation of platelets in type 2 diabetic patients with insufficient platelet response to aspirin.
PMID: 23801816 [PubMed - in process] (Source: Diabetes Care)
Source: Diabetes Care - July 1, 2013 Category: Endocrinology Authors: Araki S, Matsuno H, Haneda M, Koya D, Kanno Y, Kume S, Isshiki K, Araki H, Ugi S, Kawai H, Kashiwagi A, Uzu T, Maegawa H Tags: Diabetes Care Source Type: research
Medical management of critical limb ischaemia: where do we stand today?
This article is protected by copyright. All rights reserved. (Source: Journal of Internal Medicine)
Source: Journal of Internal Medicine - June 26, 2013 Category: Internal Medicine Authors: Matthew A. Lambert, Jill J. F. Belch Tags: Review Source Type: research
Peripheral arterial disease - Diagnosis and management in general practice.
DISCUSSION: Careful history, clinical examination, and measurement of ankle-brachial index remain the initial means of diagnosing PAD. More detailed anatomic information from duplex imaging, computed tomography angiography and magnetic resonance angiography, is usually unnecessary unless endovascular or surgical intervention is being considered, or if abdominal aortic aneurysm or popliteal aneurysm need to be excluded. Management is focused on lifestyle modification, including smoking cessation and exercise; medical management of atherosclerotic risk factors, including antiplatelet agents, statins, antihypertensive therapy...
Source: Australian Family Physician - June 1, 2013 Category: Primary Care Authors: Au TB, Golledge J, Walker PJ, Haigh K, Nelson M Tags: Aust Fam Physician Source Type: research
Administration of cilostazol, an antiplatelet, to patients with acute-stage cerebral infarction and its effects on plasma substance P level and latent time of swallowing reflex.
Conclusion: The LTSR values was significantly shortened within 180 days after the start of cilo treatment, but the result was not well explained by substance P levels as far as these were measured using the plasma, probably because this substance had diluted during blood circulation. However, it will become clinically usable as a single swallowing index, if in the future some ingeneus method of its measurement is developed. A larger-scale study would also be needed to confirm our conclusion from this pilot study. PMID: 23470806 [PubMed - in process] (Source: Journal of Nippon Medical School)
Source: Journal of Nippon Medical School - May 26, 2013 Category: Universities & Medical Training Authors: Abe A, Nishiyama Y, Hagiwara H, Okubo S, Ueda M, Katsura K, Katayama Y Tags: J Nippon Med Sch Source Type: research
Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease
Abstract Diabetic patients are at the high risk of foot ulcerations that may lead to limb amputations with important socio economic impact. Peripheral vascular disease may be frequently associated in diabetes mellitus type II with its main symptom, intermittent claudication. Many studies reported the known efficacy of cilostazol in treating vascular claudication. Metalloproteinase‐9 (MMP‐9) seems to be a biochemical marker implicated in chronic wounds and in particular in diabetic foot ulcers. Cilostazol seems to have also a lowering effect on levels of MMP‐9 and this may suggest a beneficial effect in order to preve...
Source: International Wound Journal - May 15, 2013 Category: Surgery Authors: Stefano de Franciscis, Luca Gallelli, Luigi Battaglia, Vincenzo Molinari, Rossella Montemurro, Domenico M. Stillitano, Gianluca Buffone, Raffaele Serra Tags: ORIGINAL ARTICLE Source Type: research
Biochemical study of the effects of cilostazol in rats subjected to acute ischemia and reperfusion of hind limbs.
CONCLUSION: Cilostazol had no protective effect on ischemic acute reperfusion of hind limbs of rats in this model. PMID: 23702938 [PubMed - as supplied by publisher] (Source: Acta Cirurgica Brasileira)
Source: Acta Cirurgica Brasileira - May 1, 2013 Category: Surgery Authors: Souza Júnior SS, Moreira Neto AA, Schmidt Júnior AF, Lemos JB, Rodrigues OR Tags: Acta Cir Bras Source Type: research
Cilostazol attenuates hepatic stellate cell activation and protects mice against carbon tetrachloride‐induced liver fibrosis
ConclusionsCilostazol could alleviate hepatic fibrogenesis induced by CCl4. Our data indicate the possibility of a direct effect of cilostazol on HSC activation in vivo, which is pivotal for liver pathogenesis. Given its clinical availability and safety, it may be a novel therapeutic intervention for chronic liver diseases. (Source: Hepatology Research)
Source: Hepatology Research - April 19, 2013 Category: Internal Medicine Authors: Shunichi Saito, Koichiro Hata, Keiko Iwaisako, Atsuko Yanagida, Masatoshi Takeiri, Hirokazu Tanaka, Shoichi Kageyama, Hirofumi Hirao, Kazuo Ikeda, Masataka Asagiri, Shinji Uemoto Tags: Original Article Source Type: research
Efficacy and Safety of Adjunctive Cilostazol to Dual Antiplatelet Therapy After Stent Implantation: An Updated Meta-Analysis of Randomized Controlled Trials
Conclusions: When compared to the currently recommended DAT, triple antiplatelet therapy with cilostazol can reduce repeat revascularization with no increase in the risk of bleeding. (Source: Journal of Cardiovascular Pharmacology and Therapeutics)
Source: Journal of Cardiovascular Pharmacology and Therapeutics - April 11, 2013 Category: Cardiology Authors: Ding, X. L., Xie, C., Jiang, B., Gao, J., Zhang, L. L., Zhang, H., Zhang, J. J., Miao, L. Y. Tags: Clinical Studies Source Type: research
Cilostazol inhibits accumulation of triglycerides in a rat model of carotid artery ligation
Conclusions: Our results indicate that CLZ can inhibit the ubiquitous accumulation of TG in arterial tissues, possibly by ameliorating tissue ischemia. CLZ may be useful in improving arterial tissue hemodynamics and lipid metabolism.Clinical Relevance: Triglyceride (TG) accumulation in arterial tissue is associated with the development of cardiovascular disease; however, the underlying mechanism remains unclear. Cilostazol, an antiplatelet and vasodilating drug, has been widely used for patients with peripheral artery occlusive disease to improve intermittent claudication. This study examined the effect of cilostazol on TG...
Source: Journal of Vascular Surgery - April 8, 2013 Category: Surgery Authors: Hiroki Tanaka, Nobuhiro Zaima, Hideki Ito, Katsuji Hattori, Naoto Yamamoto, Hiroyuki Konno, Mitsutoshi Setou, Naoki Unno Tags: Basic research studies Source Type: research
Cilostazol protects vessels against hyperglycemic injury and accelerates healing after implantation of drug-eluting stent in a type 1 diabetes mellitus rat aorta stent model
Abstract: Objective: Cilostazol, a selective phosphodiesterase-3 (PDE-3) inhibitor, can effectively suppress platelet activation and attenuate the increase in carotid intima-media thickness in diabetes mellitus (DM) patients. Therefore, we investigated whether cilostazol had effects on the healing process after implantation of a drug-eluting stent (DES) in a rat model of type 1 DM.Methods and results: Streptozotocin-induced DM rats were divided into 2 groups in which cilostazol (30 mg/kg/day; DM-Cilostazol) or vehicle (DM-Vehicle) was orally administered. Age-matched rats treated with the vehicle were used as a control gr...
Source: Atherosclerosis - April 4, 2013 Category: Cardiology Authors: Jin Sook Kwon, Yong Sook Kim, Hyang Hee Cho, Hae Jin Kee, Moon Hwa Hong, Wan Seok Kang, Hye-yun Jeong, Myung Ho Jeong, Youngkeun Ahn Tags: Vascular Biology, Hemostasis, Oxidative Stress Source Type: research
A systematic review to evaluate the effectiveness of carnitine supplementation in improving walking performance among individuals with intermittent claudication
Conclusions: Most trials demonstrated a small or modest improvement in walking performance with administration of PLC or l-carnitine. These findings were largely independent of level or quality of evidence, while there was some evidence that intravenous administration was more effective than oral administration and those with severe claudication may achieve greater benefits than those with moderate claudication. Routine carnitine supplementation in the form of PLC may therefore be a useful adjunct therapy for management of intermittent claudication. Further research is warranted to determine the optimal form, duration, dos...
Source: Atherosclerosis - April 3, 2013 Category: Cardiology Authors: Christopher L. Delaney, J. Ian Spark, Jolene Thomas, Yew Toh Wong, Lok Tsung Chan, Michelle D. Miller Tags: Reviews Source Type: research
Cilostazol for the Prevention of Acute Progressing Stroke: A Multicenter, Randomized Controlled Trial
Conclusions: Cilostazol failed to show a preventive effect against acute progressing stroke. However, the tendency to reduce progressing stroke and the results of stratified analyses may encourage additional studies to clarify the effect of cilostazol in the treatment of acute ischemic stroke. (Source: Journal of Stroke and Cerebrovascular Diseases)
Source: Journal of Stroke and Cerebrovascular Diseases - April 1, 2013 Category: Neurology Authors: Hiroaki Shimizu, Teiji Tominaga, Akira Ogawa, Takamasa Kayama, Kazuo Mizoi, Kiyoshi Saito, Yasuo Terayama, Kuniaki Ogasawara, Etsuro Mori, Tohoku Acute Stroke Progressing Stroke Study Group Tags: Original Articles Source Type: research
EMA recommends restricting cilostazol use for PAD
The Europeans Medicines Agency has recommended restricting the use of cilostazol in patients with intermittent claudication. Use should be avoided in those with cardiac problems or on dual anticoagulants. (Source: theHeart.org)
Source: theHeart.org - March 22, 2013 Category: Cardiology Source Type: news
EMA Recommends Restricting Cilostazol Use for PADEMA Recommends Restricting Cilostazol Use for PAD
The Europeans Medicines Agency has recommended restricting the use of cilostazol in patients with intermittent claudication. Use should be avoided in those with cardiac problems or on dual anticoagulants News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 22, 2013 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news
EU medicines agency to restrict use of Otsuka drug
LONDON (Reuters) - The European Medicines Agency said on Friday it was recommending restricting the use of medicines containing cilostazol, sold by Otsuka under the brand name Pletal, following concerns over side effects. (Source: Reuters: Health)
Source: Reuters: Health - March 22, 2013 Category: Consumer Health News Tags: healthNews Source Type: news